ATRA
Atara Biotherapeutics, Inc
stockNASDAQ
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company's namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 9.43 | 2026-10-22 | -6.26% | 6.582 |
| 1M | 8.05 | 2026-09-29 | +9.81% | 2.416 |
| 3M | 8.06 | 2026-07-29 | +9.68% | 0.777 |
| 6M | 4.60 | 2026-04-29 | +92.17% | 0.194 |
| 1Y | 14.06 | 2025-10-29 | -37.13% | 1.076 |
| 2Y | 8.87 | 2024-10-29 | -0.34% | — |
| 5Y | 387.00 | 2021-10-29 | -97.72% | 1.905 |
Atara Biotherapeutics, Inc (NASDAQ:ATRA) stock price today is $8.84, and today's volume is 747. ATRA is up 2.079% today. The 30 day average volume is 32,567. ATRA market cap is $88.73M with 10.04M shares outstanding.